

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Huashi Group Holdings Limited

华视集团控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1111)

APPOINTMENT OF EXECUTIVE DIRECTOR AND VICE CHAIRMAN OF THE BOARD

The Board hereby announces that with effect from 27 March 2025, Ms. Chen Jizhen has been appointed as an executive director of the Company and vice chairman of the Board.

The board of directors (the “**Board**”) of Huashi Group Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that Ms. Chen Jizhen (“**Ms. Chen**”) has been appointed as an executive director of the Company and vice chairman of the Board with effect from 27 March 2025.

Biographical details of Ms. Chen are set out below:

Ms. Chen Jizhen, aged 34, joined the Group in March 2023 as manager of the legal department of Huashi Zhongguang International Media (Wuhan) Co., Ltd. (華視中廣國際傳媒(武漢)有限責任公司) (“**Huashi Zhongguang**”), an indirect wholly-owned subsidiary of the Company. Ms. Chen was promoted to general manager of the legal department of Huashi Zhongguang in February 2024, and acted as the assistant to the chairman of the Board of the Group.

Prior to joining the Group, Ms. Chen served as an internal medicine physician at the Wuhan University Hospital (武漢大學醫院) from July 2018 to May 2019, a pediatric healthcare physician at the Wuxi No. 8 People’s Hospital (無錫市第八人民醫院) from June 2019 to August 2022, and also an assistant to the director of the legal department at Jointown Pharmaceutical Group Co., Ltd. (九州通醫藥集團股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 600998) from September 2022 to February 2023. She obtained the resident physician standardized training certificate from the National Health Commission of the People’s Republic of China in April 2019, and obtained a bachelor’s degree in medicine in June 2015 and a master’s degree in medicine in June 2018 from the Hubei University of Chinese Medicine (湖北中醫藥大學).

Ms. Chen has entered into a service contract with the Company for a fixed term of three years commencing on 27 March 2025, subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”), the articles of association of the Company, other applicable rules and laws, and unless otherwise terminated by either party by giving not less than three months’ written notice to the other or otherwise in accordance with other terms of the service contract. Pursuant to the articles of association of the Company and the Listing Rules, Ms. Chen shall hold office from her appointment date until the next following annual general meeting of the Company after her appointment and shall then be eligible for re-election at that meeting. Thereafter, she shall be subject to retirement by rotation at least once every 3 years at subsequent annual general meetings of the Company since her last re-election. Pursuant to her service contract, Ms. Chen is entitled to receive a director’s fee of HK\$18,000 per month, which was determined with reference to Ms. Chen’s qualifications, experience and level of responsibilities undertaken and the prevailing market conditions.

Ms. Chen is the sister of Mr. Chen Jicheng, who is the chairman of the Board, an executive director, chief executive officer and a controlling shareholder of the Company.

As at the date of this announcement, save as disclosed above, Ms. Chen has confirmed that she (i) does not hold and has not held any other directorships in the last three years in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold any position in the Company or any of its subsidiaries; (iii) does not have any relationship with any directors, senior management and substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest in the shares or the underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Ms. Chen has confirmed that there are no other matters relating to the aforementioned appointment of Ms. Chen that need to be brought to the attention of the shareholders of the Company or the Stock Exchange and there is no other information that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend its warmest welcome to Ms. Chen for joining the Board.

By Order of the Board
Huashi Group Holdings Limited
Chen Jicheng
Chairman and Chief Executive Officer

Wuhan, the PRC, 27 March 2025

As at the date of this announcement, the Board comprises Mr. Chen Jicheng, Ms. Chen Jizhen, Ms. Wang Shujin, Mr. Zhang Bei and Ms. Xue Yuchun as executive directors, and Dr. He Weifeng, Mr. Peng Litang, Mr. Li Guangdou and Mr. How Sze Ming as independent non-executive directors.